
Quad-class exposed RRMM in real life (Flatiron, n=241 starting next therapy, median 5 prior lines): median EFS 5.0 mo, OS 15.6 mo. ~25% died before each subsequent line. GPRC5D bispecifics were the most used next option. #mmsm doi.org/10.1182/bloodadvance…






























